Graft Versus Host Disease (GVHD) (Immunology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease – Drugs In Development, 2021, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 8, 37, 21, 6, 48, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 15 and 2 molecules, respectively.

Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).

– The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

9 Meters Biopharma Inc

Abbisko Therapeutics Co Ltd

AbbVie Inc

Accro BioScience (Suzhou) Co Ltd

Actitrexx GmbH

Adienne Pharma & Biotech SA

Agenus Inc

Alphamab Oncology

AltruBio Inc

Amgen Inc

AnaMar AB

AnaptysBio Inc

ASC Therapeutics Inc

AstraZeneca Plc

Athersys Inc

Athos Therapeutics Inc

Autolus Therapeutics Plc

Avalon GloboCare Corp

Bellicum Pharmaceuticals Inc

Biocon Ltd

Biogen Inc

BioIncept LLC

BioTheryX Inc

BlueRock Therapeutics LLC

Boryung ViGenCell Inc

Bristol Myers Squibb Co

Capricor Therapeutics Inc

Cellect Biotechnology Ltd

Cellective BioTherapy Inc

Cellenkos Inc

Cellestia Biotech AG

Cellix Bio Pvt Ltd

CELLnLIFE Inc

Celltrion Inc

Cellvation Inc

CheckPoint Immunology Inc

Claritas Pharmaceuticals Inc

Clinigen Group Plc

Connext Co Ltd

CSL Ltd

CTI BioPharma Corp

Cue Biopharma Inc

Cynata Therapeutics Ltd

Cytopeutics Pte Ltd

Daewoong Pharmaceutical Co Ltd

Dianomi Therapeutics Inc

Dualogics Corp

Educell doo

Eli Lilly and Co

enGene Inc

Enlivex Therapeutics Ltd

EV Therapeutics Inc

Evive Biotech

ExCellThera Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Genentech USA Inc

GlaxoSmithKline Plc

Glia LLC

Grifols SA

Humanigen Inc

iCELL Biotechnology Co Ltd

Immplacate

Immune Modulation Inc

ImmuneTarget Inc

Imstem Biotechnology Inc

Incyte Corp

Inspyr Therapeutics Inc

Jazz Pharmaceuticals Plc

JN Biosciences LLC

Kadmon Corp LLC

Kamada Pharmaceuticals

Kiniksa Pharmaceuticals Ltd

Kymab Ltd

MaaT Pharma

Machavert Pharmaceuticals LLC

Magenta Therapeutics Inc

Mallinckrodt Plc

Medexus Pharmaceuticals Inc

Medicenna Therapeutics Corp

Mediolanum farmaceutici SpA

Medsenic SAS

Merck & Co Inc

Mereo Biopharma Group Plc

Mesoblast Ltd

Millennium Pharmaceuticals Inc

MitoImmune Therapeutics Inc

NapaJen Pharma Inc

Neovii Pharmaceuticals AG

Nurix Therapeutics Inc

OncoC4 Inc

Orca Biosystems Inc

OSE Immunotherapeutics

Panorama Researchama Research

Pfizer Inc

Platinum Biotech (Beijing) Co Ltd

Pluristem Therapeutics Inc

Precision Biosciences Inc

REGiMMUNE Corp

Rheos Medicines Inc

SCM lifescience Co Ltd

Seagen Inc

Secura Bio Inc

Seres Therapeutics Inc

Shenzhen Chipscreen Biosciences Co Ltd

Sino Biopharmaceutical Ltd

STERO Biotechs Ltd

StingInn LLC

Suzhou Connect Biopharmaceuticals Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

Swedish Orphan Biovitrum AB

Syndax Pharmaceuticals Inc

Synthetic Biologics Inc

Takeda Pharmaceutical Co Ltd

Targazyme Inc

TCF GmbH

TeraImmune Inc

Tianjin Angsai Cell Genetic Engineering Co Ltd

TreeFrog Therapeutics SAS

Triursus Therapeutics Inc

United BioPharma Inc

Vault Pharma Inc

VectivBio Holding AG

Visterra Inc

Xenikos BV

Xenothera SAS

Table of Contents

Table of Contents

Introduction

Graft Versus Host Disease (GVHD) - Overview

Graft Versus Host Disease (GVHD) - Therapeutics Development

Graft Versus Host Disease (GVHD) - Therapeutics Assessment

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development

Graft Versus Host Disease (GVHD) - Drug Profiles

Graft Versus Host Disease (GVHD) - Dormant Projects

Graft Versus Host Disease (GVHD) - Discontinued Products

Graft Versus Host Disease (GVHD) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Graft Versus Host Disease (GVHD) – Pipeline by 9 Meters Biopharma Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Abbisko Therapeutics Co Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by AbbVie Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Actitrexx GmbH, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Adienne Pharma & Biotech SA, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Agenus Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Alphamab Oncology, 2021

Graft Versus Host Disease (GVHD) – Pipeline by AltruBio Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Amgen Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by AnaMar AB, 2021

Graft Versus Host Disease (GVHD) – Pipeline by AnaptysBio Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by ASC Therapeutics Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by AstraZeneca Plc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Athersys Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Athos Therapeutics Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Autolus Therapeutics Plc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Avalon GloboCare Corp, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Bellicum Pharmaceuticals Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Biocon Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Biogen Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by BioIncept LLC, 2021

Graft Versus Host Disease (GVHD) – Pipeline by BioTheryX Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by BlueRock Therapeutics LLC, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Boryung ViGenCell Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Bristol Myers Squibb Co, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Capricor Therapeutics Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Cellect Biotechnology Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Cellective BioTherapy Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Cellenkos Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Cellestia Biotech AG, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Cellix Bio Pvt Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by CELLnLIFE Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Celltrion Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Cellvation Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by CheckPoint Immunology Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Claritas Pharmaceuticals Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Kamada Pharmaceuticals, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Kiniksa Pharmaceuticals Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Kymab Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by MaaT Pharma, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Machavert Pharmaceuticals LLC, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Magenta Therapeutics Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Mallinckrodt Plc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Medexus Pharmaceuticals Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Medicenna Therapeutics Corp, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Mediolanum farmaceutici SpA, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Medsenic SAS, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Merck & Co Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Mereo Biopharma Group Plc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Mesoblast Ltd, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Millennium Pharmaceuticals Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by MitoImmune Therapeutics Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by NapaJen Pharma Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Neovii Pharmaceuticals AG, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Nurix Therapeutics Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by OncoC4 Inc, 2021

Graft Versus Host Disease (GVHD) – Pipeline by Orca Biosystems Inc, 2021

Graft Versus Host Disease (GVHD) – Dormant Projects, 2021

Graft Versus Host Disease (GVHD) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports